Analytical Data
-
Gene name
cap5A
- Application
-
Alternative Names
cap5A；Capsular polysaccharide type 5 biosynthesis Protein cap5A
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P95695
-
Expression Region
1-222aa
-
AA Sequence
MESTLELTKIKEVLQKNLKILIILPLLFLIISAIVTFFVLSPKYQANTQILVNQTKGDNPQFMAQEVQSNIQLVNTYKEIVKSPRILDEVSKDLNDKYSPSKLSSMLTITNQENTQLINIQVKSGHKQDSEKIANSFAKVTSKQIPKIMSVDNVSILSKADGTAVKVAPKTVVNLIGAFFLGLVVALIYIFFKVIFDKRIKDEEDVEKELGLPVLGSIQKFN
-
Molecular Weight
26.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Cap5A is a critical virulence factor found in certain pathogenic bacteria, notably within the Capnocytophaga species. This protein plays an essential role in the synthesis of capsular polysaccharides, which are crucial for bacterial evasion of the host immune system and adherence to host tissues. The study of Cap5A recombinantly expressed in laboratory settings has gained significant interest due to its potential application in vaccine development and therapeutic interventions. By understanding the structure, function, and genetic regulation of Cap5A, researchers aim to elucidate its role in pathogenicity and explore its potential as a target for novel antimicrobial strategies. Recombinant Cap5A can be utilized to investigate its interactions with host cells and to assess its immunogenic properties, paving the way for the development of effective vaccines or diagnostics against infections caused by Capnocytophaga and related pathogens. Additionally, insights gained through Cap5A research can contribute to broader microbiological studies, enhancing our understanding of bacterial evolution and host-pathogen interactions. As antibiotic resistance continues to rise, exploring the biochemical pathways and immunological responses associated with Cap5A is increasingly crucial for public health and disease management. This research not only aids in the comprehension of bacterial virulence mechanisms but also opens avenues for innovative approaches to combat bacterial infections more effectively.
